Malignant Neoplasm
214
42
57
103
Key Insights
Highlights
Success Rate
79% trial completion
Published Results
41 trials with published results (19%)
Research Maturity
103 completed trials (48% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
12.6%
27 terminated out of 214 trials
79.2%
-7.3% vs benchmark
4%
9 trials in Phase 3/4
40%
41 of 103 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 103 completed trials
Clinical Trials (214)
Web-Based Family Outreach Program for Cancer Prevention in High-Risk Families
A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to Treatment
Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers
Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors
Construction and Evaluation of Tumor Immunotherapy and Organ Damage Early Warning System Based on Multi-omics
Collaborative Targeted Case Management in Improving Functional Status in Patients With Stage III-IV Cancer
A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)
Novel Outreach Methods to Increase Enrollment to Early Phase Clinical Trials
Project: Every Child for Younger Patients With Cancer
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
Measuring Changes in Body Composition and Physical Function in Patients With Childhood Cancers
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
New Assessment System in Measuring Symptom Distress in Cancer Patients
Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"